Industry

DUBLIN–(BUSINESS WIRE)–The “Global T-cell lymphoma Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering. The T-cell lymphoma market is poised to grow by $768.07 mn during 2022-2026, accelerating at a CAGR of 8.21% during the forecast period. The report on the T-cell lymphoma market provides a holistic analysis, market size and forecast, trends, growth drivers, … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting, which will take place November 3 – 6, 2022 in … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Nerve Repair & Regeneration Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product, Biomaterials, Application, Nerve Repair & Regeneration Applications” report has been added to ResearchAndMarkets.com’s offering. The nerve repair & regeneration market is expected to reach US$ 12,514.06 million by 2028 from US$ 6,607.71 million in 2021; it is … [Read more…]

-Founded by leading experts in covalent chemistry, proteomics, and computational sciences from Stanford University and Harvard Medical School -Series A financing led by Sanofi Ventures with participation from Atlas Venture, Access Biotechnology, Vertex Ventures HC, Digitalis Ventures, Alexandria Venture Investments, and others CAMBRIDGE, Mass.–(BUSINESS WIRE)–Matchpoint Therapeutics, a biotechnology company founded to leverage the power of … [Read more…]

If approved, BRUKINSA would be the only BTK inhibitor for CLL in the European Union to achieve superior efficacy versus standard of care in head-to-head trials With significantly lower rates of atrial fibrillation/flutter compared to standard of care, BRUKINSA has potential to offer a more tolerable treatment option for certain patients CAMBRIDGE, Mass. & BASEL, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Antibody Library Technology Market Analysis, by Technology, by Application, by End User, and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The antibody library technology market size is estimated to be USD 145.71 million in 2021 and is expected to witness a CAGR of 4.76% during the … [Read more…]

Data from the INCREASE open label extension study of Tyvaso® detail its long-term safety and tolerability in pulmonary hypertension associated with interstitial lung disease Data from the FREEDOM-EV open label extension study of Orenitram® details an association with improved survival and, separately, its effects as part of a combination therapy regimen in patients with pulmonary … [Read more…]

Revenues of $80.9 Billion Grew 12% Year-Over-Year, with Diversified Growth across Optum and UnitedHealthcare Earnings from Operations were $7.5 Billion Cash Flows from Operations were $18.5 Billion; Adjusted Cash Flows from Operations were $8.8 Billion, 1.6x Net Income Net Earnings $5.55 Per Share; Adjusted Earnings $5.79 Per Share MINNETONKA, Minn.–(BUSINESS WIRE)–Strong and well-balanced performance continued … [Read more…]

LILLE, France–(BUSINESS WIRE)–#1stpatient–This replaces the announcement made on October 13th at 04:05 AM ET, due to the following correction: In paragraph 4: the mention of the trial conducted by the CRO, Artialis, was added. 4Moving Biotech Announces First Patient Enrolled in Phase I Clinical Trial on Osteoarthritis 4Moving Biotech, a biotechnology company and subsidiary of … [Read more…]

GUANGZHOU, China–(BUSINESS WIRE)–#Asthma–Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala® (mepolizumab), to US-sourced and EU-sourced reference product in normal healthy volunteers. The clinical study is a randomized, double-blind, parallel … [Read more…]